195 related articles for article (PubMed ID: 12165403)
1. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
Cutillas B; Ambrosio S; Unzeta M
Neurosci Lett; 2002 Aug; 329(2):165-8. PubMed ID: 12165403
[TBL] [Abstract][Full Text] [Related]
2. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
Perez V; Unzeta M
Neurochem Int; 2003 Feb; 42(3):221-9. PubMed ID: 12427476
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
4. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Unzeta M; Sanz E
Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
[TBL] [Abstract][Full Text] [Related]
5. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine (PF 9601N), a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells.
Perez V; Romera M; Lizcano JM; Marco JL; Unzeta M
J Pharm Pharmacol; 2003 May; 55(5):713-6. PubMed ID: 12831516
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
9. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Waldmeier PC; Spooren WP; Hengerer B
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):526-37. PubMed ID: 11138845
[TBL] [Abstract][Full Text] [Related]
10. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
Sanz E; Romera M; Bellik L; Marco JI; Unzeta M
Med Sci Monit; 2004 Dec; 10(12):BR477-84. PubMed ID: 15567979
[TBL] [Abstract][Full Text] [Related]
11. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
12. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
Macinnes N; Duty S
Br J Pharmacol; 2004 Dec; 143(8):952-9. PubMed ID: 15545290
[TBL] [Abstract][Full Text] [Related]
13. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.
Guan J; Krishnamurthi R; Waldvogel HJ; Faull RL; Clark R; Gluckman P
Brain Res; 2000 Mar; 859(2):286-92. PubMed ID: 10719076
[TBL] [Abstract][Full Text] [Related]
14. Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course.
Fernandes A; de Oliveira EF; de Rezende IC; Ponzoni S
Brain Res; 2010 Mar; 1317():277-85. PubMed ID: 20045397
[TBL] [Abstract][Full Text] [Related]
15. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.
Sanz E; Quintana A; Battaglia V; Toninello A; Hidalgo J; Ambrosio S; Valoti M; Marco JL; Tipton KF; Unzeta M
J Neurochem; 2008 Jun; 105(6):2404-17. PubMed ID: 18331475
[TBL] [Abstract][Full Text] [Related]
16. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
[TBL] [Abstract][Full Text] [Related]
17. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
Kearns CM; Gash DM
Brain Res; 1995 Feb; 672(1-2):104-11. PubMed ID: 7749731
[TBL] [Abstract][Full Text] [Related]
18. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
